Decreased BIM expression in BCL2-negative follicular lymphoma: a potential mechanism for resistance to apoptosis

Socha, Daniel; Zhao, Xiaoxian; Bodo, Juraj; Durkin, Lisa; Hsi, Eric D.

doi:10.1016/j.humpath.2020.09.016

Cited by 2 publications

(1 citation statement)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[29,30] And Bcl2 inhibits the pro-apoptotic effect of Bax by forming a dimer with Bax, thereby exerting an anti-apoptotic effect. [31] Previous study has shown that apoptosis is associated with heart failure in both human and animal models, and that apoptosis is involved in the progression from cardiac hypertrophy to heart failure. [32] Moreover, cardiomyocyte apoptosis plays an important role in the development of left ventricle dysfunction in heart failure with reduced ejection fraction, and cardiomyocyte loss is a well-defined feature of heart failure with reduced ejection fraction.…”

Section: Discussionmentioning

confidence: 99%

Value of Bax and Bcl2 expression in peripheral blood mononuclear cells for clinical prognosis of patients with chronic heart failure

Chen,

Li,

Yang

et al. 2024

Medicine

View full text Add to dashboard Cite

To investigate the expression of Bax and Bcl2 protein in peripheral blood mononuclear cells (PBMC) of patients with chronic heart failure (CHF), and to analyze their value for predicting major adverse cardiovascular event (MACE) in CHF patients. A total of 154 fasting venous blood samples from CHF patients were collected in our hospital from January 2017 to June 2019, and they were divided into 2 group according to whether MACE occurred during 3 years follow-up, MACE group and No-MACE group. Levels of Bax and Bcl2 protein expression in PBMC of CHF patients using enzyme-linked immunosorbent assay (ELISA), and then evaluated the predictive power of Bax and Bcl2 expression for MACE using logistic regression analysis and ROC curve. 62 (40.26%) of 154 CHF patients occurred MACE during follow-up, and there were significant differences in age, diabetes, LVEF, LDL-C and NYHA grade between MACE group and No-MACE group. Levels of Bax protein expression in PBMC of CHF patients in MACE group were significantly higher than those in No-MACE group, while levels of Bcl2 protein expression were significantly lower than those in No-MACE group, and Bax and Bcl2 protein levels increased and decreased with NYHA grades in MACE group and No-MACE group, respectively. Results of univariate and multivariate logistic regression analysis showed that Bax (OR, 1.026; 95% CI, 1.003–1.049; P = .027) and Bcl2 levels (OR, 0.952; 95% CI, 0.908–0.998; P = .041) were independent predictive factors for MACE in CHF patients. In addition, Bax and Bcl2 levels could be used to differentiate CHF patients at risk for MACE with an AUC of 0.744 (95% CI: 0.660–0.827) and an AUC of 0.743 (95% CI: 0.667–0.819), respectively. Levels of Bax and Bcl2 protein in PBMC could be used as independent predictive factors for MACE in CHF patients.

show abstract